David Ramsay returns as interim CFO at Halozyme (HALO)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while it continues an active search for a permanent CFO. Ramsay previously served as Halozyme’s CFO across multiple periods and has more than 30 years of financial leadership in biotechnology.
As Interim CFO he will receive a monthly salary of $50,000 and an equity grant of 10,000 restricted stock units that vest on June 30, 2026, subject to continued employment and a one-year holding period. If he remains Interim CFO on July 1, 2026, he will receive an additional 2,500 RSUs that vest on his employment termination date, also with a one-year holding period.
Positive
- None.
Negative
- None.
Insights
Interim CFO appointment brings experienced insider back with moderate equity incentives.
Halozyme is installing David Ramsay as Interim CFO, drawing on his prior CFO tenure and broader biotech finance experience. This helps maintain continuity in financial oversight while the company searches for a permanent finance leader.
His package combines $50,000 monthly cash compensation with time-based RSUs, aligning some of his pay with shareholder outcomes over the coming period. The role is explicitly interim, so future disclosures about the permanent CFO hire will complete the leadership picture.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) On March 12, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”), effective March 23, 2026. Since April 2017, Mr. Ramsay (age 61) has served as a member of the Board of Directors of Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Since 2017, he has also served on the board of directors of Exuma Biotech, Inc., a privately held biotechnology company. Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications, from February 2018 until its acquisition by Allergan plc in October 2018. Mr. Ramsay previously served as the Company’s Chief Financial Officer from 2003 to 2009 and from 2013 until 2015. He also served as the Company’s Vice President, Corporate Development from 2009 to 2013. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.
There are no family relationships between Mr. Ramsay and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Mr. Ramsay does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.
In his role as Interim CFO, Mr. Ramsay will be paid a monthly salary of $50,000. Mr. Ramsay will also receive an equity grant consisting of 10,000 restricted stock units (“RSUs”) that will vest on June 30, 2026, provided he remains employed with the Company through such date, and be subject to a one-year holding period from the vesting date. In the event Mr. Ramsay continues to serve as Interim CFO on July 1, 2026, he will be granted an additional 2,500 RSUs which will vest on his employment termination date and be subject to a one-year holding period from the vesting date. The RSUs will be granted under, and be subject to the terms and conditions of, the Company’s 2021 Stock Plan.
On March 12, 2026, the Company issued a press release announcing the appointment of Mr. Ramsay as Interim CFO. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibits
| Exhibit No. | Description | |||||||
99.1 | Press Release of Halozyme Therapeutics, Inc. dated March 12, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc. (Registrant) | |||||||||||||||||
Dated: | March 12, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Senior Vice President, General Counsel and Corporate Secretary | |||||||||||||||||
Exhibit 99.1
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
SAN DIEGO, March 12, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.
Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up. He previously served as Halozyme’s Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company.
During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme’s foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.
“I am thrilled to have the opportunity to work with David again,” said Dr. Helen Torley, President and Chief Executive Officer. “His deep understanding of Halozyme, combined with his exceptional capital markets expertise, investor expertise and credibility, and his longstanding record of financial leadership, makes him an invaluable partner as we advance our strategic priorities. David has made a lasting impact on Halozyme’s evolution, and we are fortunate to welcome him back into a role where his experience and leadership will be immediately impactful.”
The company’s executive search for a permanent Chief Financial Officer is well underway and progressing. Halozyme has engaged a leading executive search firm to identify candidates who bring the combination of capital markets expertise and strategy. Mr. Ramsay will remain in the role until a permanent CFO is appointed.
Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio’s hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio’s polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio’s technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme’s executive search efforts for a permanent chief executive officer, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including potential delays in hiring a permanent chief financial officer. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
FAQ
What did Halozyme Therapeutics (HALO) announce in this 8-K filing?
Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. He will oversee all financial operations while the company continues its active search for a permanent CFO, supported by an external executive search firm.
Who is David Ramsay, Halozyme’s new Interim CFO?
David Ramsay is a veteran biotechnology finance executive who previously served as Halozyme’s CFO from 2003 to 2009 and 2013 to 2015. He has over 30 years of financial leadership, including roles at Bonti, Inc., and board positions at Savara Inc. and Exuma Biotech.
How will Halozyme (HALO) compensate Interim CFO David Ramsay?
As Interim CFO, David Ramsay will receive a monthly salary of $50,000. He will also get 10,000 restricted stock units vesting June 30, 2026, plus a potential additional 2,500 RSUs if still serving on July 1, 2026, all with one-year post‑vesting holding periods.
How long will David Ramsay serve as Halozyme’s Interim CFO?
David Ramsay will serve as Interim CFO starting March 23, 2026, and remain in the role until a permanent Chief Financial Officer is appointed. His compensation structure, including potential additional RSUs after July 1, 2026, reflects this interim but open-ended timeframe.
What equity awards will Halozyme grant to Interim CFO David Ramsay?
Ramsay will receive 10,000 RSUs that vest on June 30, 2026, if he remains employed, plus a possible 2,500 additional RSUs if still Interim CFO on July 1, 2026. All RSUs carry a one‑year holding period after vesting under Halozyme’s 2021 Stock Plan.